A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Autism Spectrum Disorder

In brief

This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314 in adult participants with ASD. In Stage I of the study, participants will be randomized in 2:1 to receive daily oral doses of 1.5 milligrams (mg) RG7314 or placebo for 12 weeks. After an independent safety review, the study may proceed to Stage II. In Stage II of the study, additional participants will be randomized in 2:1 to receive daily oral doses of 4 mg RG7314 or placebo for 12 weeks. After an independent safety review, Stage III will be started wherein additional participants will be randomized in 2:1 to receive daily oral doses of 10 mg RG7314 or placebo for 12 weeks. During Stage III, safety will be reviewed by independent safety review twice and if no safety signal is observed, then additional participants will be randomized in 1:1:1 either to receive 1.5 milligrams per day (mg/day) or 10 mg/day RG7314 orally or placebo for 12 weeks in Stage IV.

Key facts

Study ID

NCT01793441

Run by

Hoffmann-La Roche

People needed

223

Starts

2013-09-01

Expected to finish

2016-09-01

Last updated by the study team

2017-02-03

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participants meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for ASD and Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10) criteria for Autism diagnosis
• SRS-2 (T-score) greater than or equal to (>/=) 66
• CGI-S >/=4 (moderately ill)
• Participants have an Intelligence Quotient (IQ) >/=70 (Wechsler Abbreviated State of Intelligence)
• A body mass index (BMI) between 18 to 40 kilograms per square meter (kg/m\^2) inclusive
• Language, hearing and vision compatible with the study measurements as judged by the investigator
• Lives with (or has substantial periods of contact with) a caregiver who is willing and able to attend visits when required, oversee the participant's compliance with protocol-specified procedures and study medication dosing, and report on the participant's status via completion of study assessments. Any period of absence must be covered by another caregiver. Non-cohabitating caregiver(s) must spend sufficient time with the participant so that, in the opinion of the investigator, the caregiver(s) can reliably assess participant's mental status, activities and behavior.

You may not qualify if…

• Alcohol and/or substance abuse/dependence during the last 12 months
• A significant risk for suicidal behavior, in the opinion of the investigator
• Systolic blood pressure greater than (>) 140 or less than (<) 90 millimeters of mercury (mm Hg), and diastolic blood pressure >90 or less than (<) 50 mm Hg
• Resting pulse rate >90 or <40 beats per minute
• Use of prohibited medications or herbal remedies within 2 weeks prior to randomization, or 5 half-lives (whichever is longer)
• Initiation of a new major change in psychological intervention within 4 weeks prior to randomization. Minor changes in ongoing treatment are not considered significant
• Participation in an investigational drug or device study within 60 days prior to randomization

Where it is running

• Study site — Phoenix, Arizona, United States
• University of California Davis — Sacramento, California, United States
• Study site — Sacramento, California, United States
• PCSD Feighner Research — San Diego, California, United States
• Study site — San Diego, California, United States
• University of California at San Francisco — San Francisco, California, United States
• Study site — San Francisco, California, United States
• Study site — Santa Ana, California, United States
• Study site — Stanford, California, United States
• DBA IMMUNOe Int'l Res Center — Centennial, Colorado, United States
• Study site — Centennial, Colorado, United States
• Yale University; Yale Child Study Center — New Haven, Connecticut, United States
• Study site — New Haven, Connecticut, United States
• Neurology offices of south florida — Delray Beach, Florida, United States
• Study site — Delray Beach, Florida, United States
• Research Centers of America, LLC — Oakland Park, Florida, United States
• Study site — Oakland Park, Florida, United States
• Compass Research — Orlando, Florida, United States
• Study site — Orlando, Florida, United States
• Emory University School of Medicine; Department of Human Genetics & Pediatrics — Decatur, Georgia, United States
• Study site — Decatur, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Study site — Chicago, Illinois, United States
• The Kennedy Krieger Institute — Baltimore, Maryland, United States
• Southwest Autism Research & Resource Center — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.